Reliable Brokers
Online Investing
Alerts & Analysis
Easy Trading

A success to be celebrated

Update : 23 Mar 2015, 06:31 PM

Bangladeshi pharmaceutical company Incepta is currently undertaking trials to allow it to market its anti-Hepatitis C drug overseas.

Its prospects are good as it has already proved it can profitably market a generic version of this medicine, at 1% of the $1,000-a-pill price for which it sells in the US.

The trials provide further evidence of the high degree of innovation and quality found in the Bangladeshi pharmaceutical sector. Not only is it efficient at producing low-cost medicines, but a growing number of companies are investing in new plants and technology to produce newer drugs.

Some  97% of the national demand is met by locally owned companies. If the TRIPS waiver for LDC countries to produce patented drugs is not extended when it becomes due to expire in December, the need for the sector to keep improving competitiveness and grow exports will become much more important.

It is encouraging that the sector’s competitive prices and high quality are already helping it sell medicines to 79 different countries, including Brazil, Kenya, and the UK.

There are good grounds to hope the sector will continue to create new jobs and generate vital foreign revenues.

Bangladesh’s pharmaceutical sector is a national success story which deserves to be heralded in a wider manner. Entrepreneurs and the government have built it into an industry that is in a position to reach beyond self sufficiency and grow globally.

It is an important example of the innovation and quality which can be made in Bangladesh.

Top Brokers